Norprolac (Quinagolide)

Quinagolide selectively activates dopamine D2 receptors in the anterior pituitary gland. This activation suppresses adenylate cyclase activity, leading to reduced secretion of prolactin. By decreasing circulating prolactin, the drug corrects the hormonal excess that causes the clinical manifestations of hyperprolactinemia.

The appropriate dose of Norprolac is determined by the prescribing clinician based on the individual’s condition, response, and tolerability. Dosage adjustments are made according to therapeutic goals and any relevant patient factors, such as renal function or concomitant medications.

Quinagolide is generally not recommended during pregnancy unless the potential benefit outweighs the risk to the fetus. It is also contraindicated while breastfeeding because the drug can be excreted in breast milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Norprolac (quinagolide) is a selective dopamine D2‑receptor agonist, similar to cabergoline and bromocriptine. Compared with bromocriptine, quinagolide often has a shorter half‑life and may be associated with fewer gastrointestinal side effects, while cabergoline typically requires less frequent dosing but carries a higher risk of valvular heart disease.

Norprolac tablets should be stored at temperatures below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Norprolac is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. Administration timing (e.g., with meals or on an empty stomach) is guided by the prescribing physician based on individual tolerability.

Serious adverse events, though rare, include valvular heart disease, impulse control disorders such as compulsive gambling, and severe hypotension. Patients should be monitored for cardiac symptoms, changes in behaviour, and any sudden drops in blood pressure, and report these promptly to their healthcare provider.

Norprolac is contraindicated in individuals with known hypersensitivity to quinagole or any excipients, patients with uncontrolled hypertension, and those taking potent dopamine antagonists. Caution is also advised for patients with significant cardiac disease, renal impairment, or a history of impulse control disorders.